T Cell News and Research

Latest T Cell News and Research

Study reveals how cancer cells escape death by lymphocytes

Immunotherapy continues to show exciting promise in more effectively combating several tumor types. Many current strategies focus on ensuring the efficient delivery of active cytotoxic cells directly to tumors.

24 Feb 2021

Researchers use powerful X-rays to analyze brain tissues of schizophrenia patients

Schizophrenia, a chronic, neurological brain disorder, affects millions of people around the world. It causes a fracture between a person's thoughts, feelings and behavior.

24 Feb 2021

Study: Abundance of iron can drive cancer cell death in neuroblastoma

Neuroblastoma is a cancer that develops in nerve tissue, most commonly in the glands around the kidneys. The gene MYCN is overexpressed in 20-25% of neuroblastoma, and MYCN-amplified neuroblastoma contributes to a considerable percentage of pediatric cancer-related deaths.

24 Feb 2021

New platform can help treat neurodegenerative diseases through regenerative medicine

Imagine if surgeons could transplant healthy neurons into patients living with neurodegenerative diseases or brain and spinal cord injuries.

24 Feb 2021

Long-lasting B cells do not recognize emerging SARS-CoV-2 variants, shows study

A new analysis of B cells and more than 1,000 different monoclonal antibodies from 8 patients with COVID-19 shows that, contrary to previous hypotheses, protective B cell responses to the SARS-CoV-2 spike protein remain stable and continue to evolve over a 5-month period, many months after the initial period of active viral replication.

23 Feb 2021

COVID-19 may alter host proteins to cause autoimmunity

To better understand the transient and chronic autoimmune symptoms caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, researchers from Memorial Sloan Kettering Cancer Center, Guizhou Medical University, and biotech company Curandis embarked on an endeavor to establish a comprehensive autoantigenome for COVID19.

23 Feb 2021

Study: Interbacterial toxins may contribute to bacterial genetic diversity

A toxin produced by bacteria as a defence mechanism causes mutations in target bacteria that could help them survive, according to a study published today in eLife.

23 Feb 2021

SARS-CoV-2 variants emerge during humoral immunity phase of acute COVID-19

A new preprint research paper posted to the bioRxiv server reports the rapid emergence of variants within an infected individual. The evolution of the virus within an infected host is not excluded by the close similarity between the consensus sequences of single-person SARS-CoV-2, since the number of viral copies is at its peak soon after infection occurs and before the host develops adaptive immunity.

23 Feb 2021

Research predicts which mammal species can spread SARS-CoV-2

Scientists worldwide are fighting to contain the ongoing COVID-19 pandemic, which has already claimed more than 2.48 million lives. Preventing spillback infections is essential to containing the pandemic. To do so, it is vital to understand the nature of the virus, i.e., its susceptibility to a range of hosts.

23 Feb 2021

New microneedle patches for delivery of psychedelic pharmaceuticals

Although one may think of psychedelic pharmaceuticals as being dangerous and detrimental, scientists have been conducting experiments and clinical trials on some of them and have obtained positive results when testing them for medical use.

23 Feb 2021

‘Resuscitating’ old antibiotics to combat the growing threat of superbugs

Holding off the rise of superbugs could be achieved by 'resuscitating' old antibiotics, with The University of Queensland researchers leading an international project to help combat the growing threat.

23 Feb 2021

Innate immune system overreacts in patients with severe COVID-19

In patients with severe COVID-19, the innate immune system overreacts. This overreaction may underlie the formation of blood clots (thrombi) and deterioration in oxygen saturation that affect the patients.

23 Feb 2021

GSK-3 inhibitors show promise in treating coronavirus infections

Researchers in the United States have suggested a new approach to treating infection with coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

23 Feb 2021

Glycan switch may explain why SARS-CoV-2 causes such variable symptoms

Researchers in Portugal have provided evidence that might explain why infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes mild or even asymptomatic illness in some individuals, but severe coronavirus disease 2019 (COVID-19) in others.

23 Feb 2021

Limiting the release of fat into the bloodstream during heart failure could help improve outcomes

University of Alberta researchers have found that limiting the amount of fat the body releases into the bloodstream from fat cells during heart failure could help improve outcomes for patients.

23 Feb 2021

New gene-editing tool enables programming of sequential cuts over time

Researchers from the University of Illinois Chicago have discovered a new gene-editing technique that allows for the programming of sequential cuts -- or edits -- over time.

23 Feb 2021

After billions of dollars and dozens of wartime declarations, why are vaccines still in short supply?

The U.S. government has invested billions of dollars in manufacturing, used a wartime act dozens of times to boost supplies and yet there's still not enough covid vaccine on the way to meet demand — or even the government's own goals for national immunization.

23 Feb 2021

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

Scientists at the University of Salzburg and Pantec Biosolutions AG have developed a laser-facilitated epicutaneous immunization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The model has induced angiotensin-converting enzyme 2 (ACE2) blocking antibodies in mice.

23 Feb 2021

L452R mutation potentially favors adaptive evolution of SARS-CoV-2

A team of scientists from the United States recently investigated the mutational signatures in the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein.

23 Feb 2021